VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
Liver and intestinal toxicology testing both grew in the quarter ended September 30, 2026. VivoSim anticipates that the customer will make NAMkind™ testing part of its regular flow of ongoing preclinical work SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc.
